| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cbc121269efbe3802650c56ef1a1e12d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_692ad7484a966f67a234f980337fea8f |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1793
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1787 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-00 |
| filingDate |
2020-07-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d016db06f16d19511413b8aaa9e2178d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a27a90036f1cbe53a6c5a456beb47251
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a97978eda8854e1ac4df34a94a877e74
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_32ae467776aa941e76debb370d382094
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c28184615f9e89bfc904388e9212b5d0 |
| publicationDate |
2021-01-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2021011799-A1 |
| titleOfInvention |
Inflammatory bowel diseases therapy involving disrupting ccr9:drd5 heteromer assembly |
| abstract |
A method for disrupting the formation of CCR9:DRD5 heteromer assembly in a subject involving administering to the subject a pharmaceutical composition having at least on disrupter agent that inhibits or blocks the interaction between CCR9 and DRD5. Also, peptides and peptide analogs for use as the disrupter agent and pharmaceutical compositions containing the peptides and peptide analogs. |
| priorityDate |
2019-07-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |